Latest Articles

Publication Date
Endometrial Cancer Market: Opportunities, Challenges, - openPR

Endometrial Cancer Market: Opportunities, Challenges, openPR

Published: Dec. 10, 2024, 7:16 a.m.
GSK Korea expands indication for Jemperli in endometrial cancer treatment - KBR

GSK Korea expands indication for Jemperli in endometrial cancer treatment KBR

Published: Dec. 10, 2024, 3:13 a.m.
The Targeted Pulse: Don’t Miss the FDA’s Latest Treatment Decisions and What a Retrospective Study Revealed in Endometrial Cancer - Targeted Oncology

The Targeted Pulse: Don’t Miss the FDA’s Latest Treatment Decisions and What a Retrospective Study Revealed in Endometrial Cancer Targeted Oncology

Published: Dec. 8, 2024, 5 p.m.
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - BioSpace

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer BioSpace

Published: Dec. 6, 2024, 8:22 a.m.
Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer - OncLive

Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer OncLive

Published: Dec. 5, 2024, 7:04 p.m.
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - The Malaysian Reserve

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer The Malaysian Reserve

Published: Dec. 5, 2024, 3:36 p.m.
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - Canada NewsWire

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer Canada NewsWire

Published: Dec. 5, 2024, 2:43 p.m.
Dramatic Spike in Molecular Testing for Endometrial Cancer Tells “Positive Story” - Oncology News Central

Dramatic Spike in Molecular Testing for Endometrial Cancer Tells “Positive Story” Oncology News Central

Published: Dec. 5, 2024, 12:54 p.m.
Dramatic Spike in Molecular Testing for Endometrial Cancer Tells “Positive Story” - oncologynewscentral.com

Dramatic Spike in Molecular Testing for Endometrial Cancer Tells “Positive Story” oncologynewscentral.com

Published: Dec. 5, 2024, 12:54 p.m.
Karyopharm Therapeutics Provides Regulatory Update on Endometrial Cancer ProgramOn December 3, 2024, Karyopharm Therapeutics Inc. released a press statement outlining a regulatory update on its endometrial cancer program. This update comes in li - Defense World

Karyopharm Therapeutics Provides Regulatory Update on Endometrial Cancer ProgramOn December 3, 2024, Karyopharm Therapeutics Inc. released a press statement outlining a regulatory update on its endometrial cancer program. This update …

Published: Dec. 4, 2024, 8:10 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!